Evidence map›Paper›PMID 37897713›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2023

Detection of brain lesions after catheter ablation depends on imaging criteria: insights from AXAFA-AFNET 5 trial.

Karl Georg Haeusler, Felizitas A Eichner, Peter U Heuschmann, Jochen B Fiebach, Tobias Engelhorn, David Callans, Tom De Potter, Philippe Debruyne, Daniel Scherr, Gerhard Hindricks and 8 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02227550 (An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02227550 phase4completednot on this map

An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation

TypeinterventionalSponsorAtrial Fibrillation NetworkRan2014 to 2017Enrolled676ConditionsAtrial FibrillationArmsVitamin K antagonist, Apixaban
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Trial
  3. [Risk of stroke during left atrial catheter ablation for atrial fibrillation].Herzschrittmachertherapie & Elektrophysiologie · 2026
    Review
  4. Article
  5. Microembolizations in the arterial cerebral circulation during atrial fibrillation ablation: cryoballoon technique advantages and neurocognitive safety-results of a prospective observational study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Observational
  6. Disturbed atrial metabolism, shear stress, and cardiac load contribute to atrial fibrillation after ablation: AXAFA biomolecule study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 17 institutions in 9 countries.

Karl Georg HaeuslerAtrial Fibrillation NETwork association (AFNET), Mendelstr. 11, 48149 Münster, Germany.ORCID 0000-0002-6389-5054
Felizitas A EichnerInstitute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany.ORCID 0000-0002-5415-0456
Peter U HeuschmannInstitute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany.ORCID 0000-0002-2681-3515
Jochen B FiebachCenter for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-7936-6958
Tobias EngelhornDepartment of Neuroradiology, University of Erlangen-Nuremberg, Erlangen, Germany.
David CallansHospital of the University of Pennsylvania, Philadelphia, USA.
Tom De PotterCardiovascular Center, OLV Hospital, Aalst, Belgium.ORCID 0000-0003-1424-114X
Philippe DebruyneHospital Imelda, Bonheiden, Belgium.ORCID 0000-0002-2627-1998
Daniel ScherrDivision of Cardiology, Medical University Graz, Austria.ORCID 0000-0001-5868-5493
Gerhard HindricksDeutsches Herzzentrum der Charité, Berlin, Germany.
Hussein R Al-KhalidiDepartment of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-1375-0487
Lluis MontHospital Clínic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.ORCID 0000-0002-8115-5906
Won Yong KimDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-1302-1671
Jonathan P PicciniDuke Clinical Research Institute (DCRI), Durham, NC, USA.ORCID 0000-0003-0772-2404
Ulrich SchottenAtrial Fibrillation NETwork association (AFNET), Mendelstr. 11, 48149 Münster, Germany.ORCID 0000-0003-1532-3315
Sakis ThemistoclakisDepartment of Cardiology, Ospedale dell'Angelo, Mestre-Venice, Italy.ORCID 0000-0002-7998-7113
Luigi Di BiaseAlbert Einstein College of Medicine at Montefiore Hospital, New York, NY, USA.ORCID 0000-0001-6508-4047
Paulus KirchhofAtrial Fibrillation NETwork association (AFNET), Mendelstr. 11, 48149 Münster, Germany.ORCID 0000-0002-1881-0197
Zimmer Biomet (Germany) · DEAarhus University Hospital · DKAlbert Einstein College of Medicine · USAtrial Fibrillation NETwork · DECharité - Universitätsmedizin Berlin · DEClinical Research Institute · USDeutsches Herzzentrum der Charité · DEDuke University · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHospital Clínic de Barcelona · ESHospital of the University of Pennsylvania · USImelda Hospital · BEMaastricht University · NLMedical University of Graz · ATOnze Lieve Vrouwziekenhuis Hospital · BEOspedale dell' Angelo · ITUniversität Hamburg · DE

Funding

British Heart Foundation FS/13/43/30324
6 · The paper itself

Abstract

aimsLeft atrial catheter ablation is well established in patients with symptomatic atrial fibrillation (AF) but associated with risk of embolism to the brain. The present analysis aims to assess the impact of diffusion-weighted imaging (DWI) slice thickness on the rate of magnetic resonance imaging (MRI)-detected ischaemic brain lesions after ablation. METHODS AND

resultsAXAFA-AFNET 5 trial (NCT02227550) participants underwent MRI using high-resolution (hr) DWI (slice thickness: 2.5-3 mm) and standard DWI (slice thickness: 5-6 mm) within 3-48 h after ablation. In 321 patients with analysable brain MRI (mean age 64 years, 33% female, median CHA2DS2-VASc 2), hrDWI detected at least one acute brain lesion in 84 (26.2%) patients and standard DWI in 60 (18.7%; P < 0.01) patients. High-resolution diffusion-weighted imaging detected more lesions compared to standard DWI (165 vs. 104; P < 0.01). The degree of agreement for lesion confirmation using hrDWI vs. standard DWI was substantial (κ = 0769). Comparing the proportion of DWI-detected lesions, lesion distribution, and total lesion volume per patient, there was no difference in the cohort of participants undergoing MRI at 1.5 T (n = 52) vs. 3 T (n = 269).

conclusionThe pre-specified AXAFA-AFNET 5 sub-analysis revealed significantly increased rates of MRI-detected acute brain lesions using hrDWI instead of standard DWI in AF patients undergoing ablation. In comparison to DWI slice thickness, MRI field strength had a no significant impact in the trial. Comparing the varying rates of ablation-related MRI-detected brain lesions across previous studies has to consider these technical parameters. Future studies should use hrDWI, as feasibility was demonstrated in the multicentre AXAFA-AFNET 5 trial.

Indexed as

Atrial FibrillationCatheter AblationBrainDiffusion Magnetic Resonance ImagingFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedAblationBrain MRIDiffusion-weighted imagingField strengthsSlice thickness

Identifiers

PMID37897713
PMCPMC10963060
OpenAlexW4388007221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.